Prevention of autoimmune rheumatic disease: State of the art and future perspectives

Annals of the Rheumatic Diseases

Volumn 69, Issue 12, 2010, Pages 2062-2066

  Klareskog, Lars ^a   Gregersen, Peter K ^b   Huizinga, Tom W J ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA; EPITOPE; HLA DR ANTIGEN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PREDNISONE; RHEUMATOID FACTOR; RO52 ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALCOHOL CONSUMPTION; ANTIBODY TITER; ARTHRITIS; AUTOIMMUNITY; CLINICAL TRIAL; CONGENITAL HEART BLOCK; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; IMMUNOMODULATION; INFLAMMATION; LIFESTYLE; MOLECULAR RECOGNITION; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; SJOEGREN SYNDROME; SMOKING CESSATION; SWEDEN; SYSTEMIC LUPUS ERYTHEMATOSUS; UNDIFFERENTIATED ARTHRITIS;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATOLOGY; RISK FACTORS; SMOKING;

EID: 78649733694     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.142109     Document Type: Review

References (57)

1. Satpute SR, Durai M, Moudgil KD. Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis. Semin Arthritis Rheum 2008;38:195-207.
2. Hayashi T, Gray CS, Chan M, et al. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci USA 2009;106:2764-9.
3. Choi JM, Kim SH, Shin JH, et al. Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis. Proc Natl Acad Sci USA 2008;105:19875-80.
4. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
5. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46.
6. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8.
7. Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005;77:1044-60.
8. Kallberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80:867-75. (Pubitemid 46668455)
9. van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 2008;10:205.
10. Ding B, Padyukov L, Lundström E, et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum 2009;60:30-8.
11. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
12. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008;58:3000-8.
13. Lundberg K, Nijenhuis S, Vossenaar ER, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005;7:R458-67.
14. Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.
15. Hill JA, Bell DA, Brintnell W, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008;205:967-79.
16. Uysal H, Bockermann R, Nandakumar KS, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009;206:449-62.
17. Yu L, Wang J, O'Dell JR, et al. Anti-dsDNA antibody assay: high specificity and sensitivity with a filtration radioassay in comparison to low specificity with the standard ELISA. J Rheumatol 2007;34:734-9.
18. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
19. Baudino L, Azeredo da Silveira S, Nakata M, et al. Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies. Springer Semin Immunopathol 2006;28:175-84.
20. Zhao Z, Weinstein E, Tuzova M, et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 2005;52:522-30.
21. Salomonsson S, Ottosson L, Säfsten P, et al. Cloning and characterization of two human Ro52-specific monoclonal autoantibodies directed towards a domain associated with congenital heart block. J Autoimmun 2004;22:167-77.
22. Salomonsson S, Sonesson SE, Ottosson L, et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005;201:11-7.
23. Strandberg LS, Ambrosi A, Jagodic M, et al. Maternal MHC regulates generation of pathogenic antibodies and fetal MHC-encoded genes determine susceptibility in congenital heart block. J Immunol 2010;185:3574-82.
24. Snir O, Widhe M, von Spee C, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009;68:736-43.
25. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008;67:1488-92.
26. Kokkonen H, Söderström I, Rocklöv J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010;62:383-91.
27. Quinn MA, Green MJ, Marzo-Ortega H, et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum 2003;48:3039-45.
28. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;56:1424-32.
29. Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004;50:849-57.
30. Finckh A, Cooper GS, Chibnik LB, et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum 2006;54:3648-54.
31. Freemer MM, King TE, Jr Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 2006;65:581-4.
32. Cooper GS, Wither J, Bernatsky S, et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford) 2010;49:2172-80.
33. Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010, Jul 23 [Epub ahead of print].
34. Rönnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990;227:207-10.
35. Rönnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001;22:427-31.
36. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-5.
37. Heliövaara M, Aho K, Aromaa A, et al. Smoking and risk of rheumatoid arthritis. J Rheumatol 1993;20:1830-5.
38. Källberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis. Estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2010. ( In press).
39. Stolt P, Yahya A, Bengtsson C, et al. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Ann Rheum Dis 2010;69:1072-6.
40. Källberg H, Jacobsen S, Bengtsson C, et al. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis 2009;68:222-7.
41. Maxwell JR, Gowers IR, Moore DJ, et al. Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. Rheumatology (Oxford) 2010;49:2140-6.
42. Jonsson IM, Verdrengh M, Brisslert M, et al. Ethanol prevents development of destructive arthritis. Proc Natl Acad Sci USA 2007;104:258-63.
43. Bengtsson C, Kapetanovic MC, Källberg H, et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 2010;69:1831-3.
44. Bos WH, Dijkmans BA, Boers M, et al. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis 2010;69:571-4.
45. Verstappen SM, McCoy MJ, Roberts C, et al. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis 2010;69:503-9.
46. Machold KP, Landewé R, Smolen JS, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 2010;69:495-502.
47. Saleem B, Mackie S, Quinn M, et al. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? Ann Rheum Dis 2008;67:1178-80.
48. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-6.
49. Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am 2010;36:213-41.
50. Strandberg L, Winqvist O, Sonesson SE, et al. Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 2008;154:30-7.
51. Wahren-Herlenius M. Immunological contribution to the pathogenesis of congenital heart block. Scand J Immunol 2010;72:171-2.
52. van der Helm-van Mil AH, Toes RE, Huizinga TW. Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis 2010;69:1694-6.
53. Olofsson P, Holmberg J, Tordsson J, et al. Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. Nat Genet 2003;33:25-32. (Pubitemid 36068678)
54. Hultqvist M, Olofsson P, Gelderman KA, et al. A new arthritis therapy with oxidative burst inducers. PLoS Med 2006;3:e348.
55. Sigurdsson S, Nordmark G, Göring HH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005;76:528-37.
56. Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006;38:550-5.
57. Niewold TB, Hua J, Lehman TJ, et al. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492-502.